Skip to main content

Patients as Research Partners

Integrated patient engagement model

CCTG uses an integrated patient engagement model that includes the patient voice in all aspects of cancer clinical trial development. A Patient Representative is not only involved in answering the scientific questions that clinical trials ask, they play an essential role on CCTG’s national disease site committee as participating members who contribute to the development and delivery of the cancer research questions. Patient Representatives ensure that patient centred outcomes included in CCTG cancer clinical trials.

A Current Oncology publication outlining the incorporation of patient engagement in the development of clinical trial at CCTG: Integrating Patient Centred Research in the Canadian Cancer Trials Group

Patient-oriented research refers to research that engages patients as partners, focuses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with stakeholders, aims to apply the knowledge generated to improve health care systems and practices. – msfhr.org - Michael Smith Foundation for Health Research

Patient engagement in clinical trail research is two-fold:

  1. Trial Participant – the human participant in the trial
  2. Patient Representative – developing and delivering the research question, ensuring: patient feasibility, outcomes that matter to patients

There are several touch points where a Patient Representative provides input as members of Scientific, Oversight and Support Committees. They are actively involved at key junctures of the CCTG Clinical Trial life cycle: Development, Review/Approval, Protocol and Consent Development, Accrual and Data Collection and at the time of Permanent Closure.

lay representative committee

Seeking Patient Representative for the Breast Disease Site Committee

Seeking Patient Representative for the Breast Disease Site Committee

The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Breast Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse national network, so we are strongly considering applications for patient representation from Quebec, New Brunswick, Nova Scotia, PEI or Newfoundland and Labrador for this position.

More >>
 
New study SC31 TEMPO testing an online program to support people with prostate cancer and their caregivers

The new SC31 TEMPO study is testing an online support program for people with prostate cancer and their caregivers

The SC31 TEMPO trial is now open and evaluating an innovative online program designed to help people with prostate cancer and their caregivers better manage the physical and emotional challenges associated with cancer and its treatment.

More >>
 
Patient Represenative Melanie Keats

Welcome to new Patient Represenative Melanie Keats

CCTG would like to welcome Melanie Keats as the new patient representative supporting the Gynecologic Disease Site Committee. Melanie resides in Halifax Nova Scotia and is a a Professor and Associate Research Scholar, Health Populations Research Institute at Dalhousie University as well as a Nova Scotia Health Authority Affiliated Scientist and Co-Director Physical Activity and Cancer (PAC) Lab.

More >>
 
June is National Indigenous History Month and Pride Month

CCTG recognizes June as National Indigenous History Month and Pride Month

June marks both National Indigenous History Month and Pride Month. It is a time to learn about and honour the diverse cultures, histories, and experiences of First Nations, Inuit, and Métis Peoples, and to celebrate the strength, resilience, and contributions of 2SLGBTQI+ communities. It is also an opportunity to reflect on our shared responsibility to advance equitable, inclusive, and culturally safe clinical trial design and conduct.

More >>